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Zn(II) and Cu(II) precipitate Ab in vitro into insoluble
aggregates that are dissolved by metal chelators. We
now report evidence that these biometals also mediate
the deposition of Ab amyloid in Alzheimer’s disease,
since the solubilization of Ab from post-mortem brain
tissue was significantly increased by the presence of
chelators, EGTA, N,N,N*,N*-tetrakis(2-pyridyl-methyl)
ethylene diamine, and bathocuproine. Efficient extrac-
tion of Ab also required Mg(II) and Ca(II). The chelators
were more effective in extracting Ab from Alzheimer’s
disease brain tissue than age-matched controls, suggest-
ing that metal ions differentiate the chemical architec-
ture of amyloid in Alzheimer’s disease. Agents that spe-
cifically chelate copper and zinc ions but preserve
Mg(II) and Ca(II) may be of therapeutic value in Alzhei-
mer’s disease.
Ab is the main component of the amyloid deposits that char-
acterize the neuropathologic lesions of Alzheimer’s disease
(AD).1 The mechanism leading to the precipitation of this nor-
mally soluble protein is unknown, but it is related to the patho-
genesis of the disorder, since all mutations linked to familial
AD alter Ab structure or metabolism (1), and the deposition of
b-amyloid in the neocortex of transgenic mice overexpressing
Ab is accompanied by most of the other neuropathological
features of AD (2). We have previously found that Zn(II),
Cu(II), and, to a lesser extent, Fe(III), at low mM concentrations,
induce the rapid aggregation of synthetic Ab (3). These transi-
tion metal ions are highly concentrated in the neocortical re-
gions most affected in AD, and all three metal ions are both
significantly elevated in the neuropil of these regions in Alz-
heimer’s disease and further concentrated within amyloid
plaque deposits (4).
We recently reported that Zn(II)- or Cu(II)-induced Ab pre-
cipitation is reversed by treating the aggregate with metal
chelators (5, 6). We hypothesized that if the metal ions within
brain amyloid mediated the assembly of Ab aggregates, then
treating tissue with metal chelators should induce the solubi-
lization of Ab. We tested this hypothesis by extracting Ab
amyloid-bearing post-mortem brain tissue in the presence and
absence of various metal ion chelators and assaying the distri-
bution of Ab within the soluble and insoluble phases.
EXPERIMENTAL PROCEDURES
Tissue Selection—Post-mortem tissues, stored at 280 °C, were ob-
tained from the National Heath and Medical Research Council-sup-
ported Brain Bank at the University of Melbourne together with ac-
companying histopathological and clinical data. AD was assessed
according to Consortium to Establish a Register for Alzheimer’s Disease
criteria (7). In order to examine the chemical architecture of the Ab
deposition that is observed in non-AD aged brain, Ab immunohisto-
chemistry was used to select age-matched control (AC) cases that did
not reach Consortium to Establish a Register for Alzheimer’s Disease
criteria and in which amyloid deposition, if present, was detectable only
in the form of diffuse plaques but not neuritic plaques.
Selection of Chelators—No available chelator is exclusively specific
for any particular metal ion; therefore, we surveyed the effects of
chelators that display various respective affinities for zinc and/or cop-
per ions relative to more abundant metal ions such as calcium and
magnesium. The pKa values of N,N,N9,N9-tetrakis(2-pyridylmethyl)eth-
ylenediamine (TPEN) are as follows: Al(III), negligible; Ca(II), 3; Cu(II),
20.2; Fe(III), 14.4; Mg(II), negligible; Zn(II), 15.4. The pKa values of
EGTA are as follows: Al(III), 13.9; Ca(II), 10.9; Cu(II), 17.6; Fe(III),
11.8; Mg(II), 5.3; Zn(II), 12.6. The pKa values of bathocuproine (BC) are
as follows: Al(III), negligible; Ca(II), negligible; Cu(II), 6.1; Cu(I), 19.1;
Fe(III), negligible; Mg(II), negligible; Zn(II), 4.1 (see Ref. 8).
Sample Preparation—The cortical meninges were removed, and gray
matter (0.5 g) was homogenized using a DIAX 900 homogenizer (Hei-
dolph & Co, Kelheim, Germany) for three 30-s periods at full speed,
with a 30-s rest between strokes, in 3 ml of ice-cold phosphate-buffered
saline (PBS), pH 7.4, containing a mixture of protease inhibitors (Bio-
Rad), with the exception of EDTA, or in the presence of either various
chelators or metal ions prepared in PBS. To obtain the PBS-extractable
fraction, the homogenate was centrifuged at 100,000 3 g for 30 min, and
the supernatant was removed and divided into 1-ml aliquots. Protein
within a 1-ml supernatant sample was precipitated using 1:5 ice-cold
10% trichloroacetic acid, and pelleted by centrifugation at 10,000 3 g
for 20 min. The pellet was prepared for polyacrylamide gel electrophore-
sis by boiling for 10 min in Tris-Tricine SDS-sample buffer containing
8% SDS, 10% mercaptoethanol, and 8 M urea. Total Ab in the cortical
samples was obtained by homogenizing in 1 ml of PBS and boiling in
sample buffer as above.
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Polyacrylamide Gel Electrophoresis and Western Blotting—Tris-
Tricine polyacrylamide gel electrophoresis was performed by loading
samples onto 10-well, 10–20% gradient gels (Novex, San Diego, CA),
followed by transfer onto 0.2-mm nitrocellulose membrane (Bio-Rad).
The Ab was detected using monoclonal antibodies WO2 (which detects
Ab40 and Ab42 at an epitope between 5–8), G210 (which is specific for
Ab species that terminate at carboxyl residue 40), or G211 (which is
specific for Ab species that terminate at carboxyl residue 42) (9), in
conjunction with horseradish peroxidase-conjugated rabbit anti-mouse
IgG (Dako, Denmark) and visualized using chemiluminescence (ECL,
Amersham Pharmacia Biotech). Each gel included two or more lanes
containing known quantities of synthetic Ab (Keck Laboratory, Yale
University, New Haven, CT) as reference standards.
Blot Scanning and Transmission Densitometry Assay for Ab—Blot
films were scanned using a Relisys scanner with transparency adapter
(Teco Information Systems, Taiwan), and densitometry was performed
using Image 1.6 software (National Institutes of Health, Bethesda,
MD). The dynamic range of the film/scanner was determined using a
step tablet (catalog no. 911ST600, Eastman Kodak Co.), a calibrated
film exposed by the manufacturer to provide steps of known increasing
intensity. The quantifiable range of signal intensity for densitometric
analysis of our Ab bands was based on the comparison with a curve
obtained by scanning and densitometry of the step tablet. The dynamic
range of the scanner was increased by using a transparency adapter
rather than reflection.
For the survey comparing levels of Ab in post-mortem brain samples
from AD cases and controls (Fig. 3), the combined signals generated
from 4.3-kDa immunoreactive Ab (apparent monomer) and 8.6-kDa
immunoreactive Ab (apparent dimer) were quantified. Successive ECL
exposure times of 2 min, 5 min, 10 min, 15 min, and 30 min were
routinely performed to establish the optimal exposure for each individ-
ual blot, so that the relative amounts of Ab measured by transmission
densitometry remained in the linear response range of the assay, while
determining at what point the signal from the Ab standards had
reached saturating intensity. Preliminary blots were routinely per-
formed to determine how the samples were to be subsequently diluted
in order to try to ensure that the Ab signals fell within the quantifiable
portion of the Ab standard curve. All of the experimental samples
extracted from the same brain specimen were initially diluted to the
same degree and included on the same blot for analysis (as in Fig. 3A).
However, it was usually not possible to determine all of the Ab readings
from one blot at one dilution. The Ab content varied broadly between
the extracted samples (note the range in Ab intensity between the
various extracts of the same brain specimens illustrated in the blots in
Fig. 3A), and therefore it was usually necessary to perform subsequent
individual blots on specific samples that had been further diluted in
order to generate Ab signals that fell within the linear range of the
standard curve.
This technique was chosen for the Ab assay in preference to enzyme-
linked immunosorbent assay, since it has the advantage of discriminat-
ing the Mr of the Ab immunoreactivity and therefore is less likely to
inappropriately detect non-Ab species such as APP fragments, like
those that have recently been found to have been inadvertently cross-
reacting with APP in an assay that previously had been considered to be
well characterized (10).
The efficiency of the trichloroacetic acid precipitation procedure was
validated by testing samples of whole human serum diluted 1:10 to
which had been added 2 mg of synthetic Ab 1–40 or Ab 1–42. Ab
recovery was assessed by extracting the precipitate into SDS sample
buffer and performing Western blot analysis against synthetic Ab
standards as above. Protein in the trichloroacetic acid pellet was esti-
mated by resuspending the pellet in water and assaying the protein
recovery using a BCA assay (Pierce). This indicated that the efficiency
of protein and Ab precipitation was approximately 90%. The efficiency
of the 8 M urea solubilization was found to be higher and less variable
that of formic acid in a parallel, blinded assay conducted independently.
All chemicals were obtained from Sigma unless otherwise indicated.
Analysis of Metals—The postcentrifugation pellets were dissolved in
4 ml of 3 N HNO3 plus 1 N HCl for 24 h and then assayed by inductively
coupled plasma atomic emission spectroscopy.
RESULTS
AD frontal cortex was compared with tissue from the same
region of AC. A survey of the effects of the chelators at a range
of concentrations (0–5 mM) on six AD cases confirmed that the
solubilization of Ab was specifically enhanced by the presence
of chelator (Fig. 1), although total trichloroacetic acid-precipi-
table protein was not affected by any of the chelators at the
concentrations tested (data not shown).
Extraction of AD brain into PBS alone liberated a small
amount of Ab into the soluble phase in every case, confirming
previous reports (11–13). In contrast, homogenization in the
presence of either EGTA or TPEN at concentrations between
0.004 and 0.1 mM significantly increased soluble Ab extraction.
The optimum concentrations of EGTA or TPEN for the resolu-
bilization of Ab varied considerably from case to case and did
not show linear concentration dependence. Typically, as illus-
trated in Fig. 1A, there was a biphasic response in Ab extrac-
tion as concentrations of EGTA or TPEN were increased. One
peak typically occurred when homogenization was performed
in the presence of 0.004 mM of either chelator. A second peak in
FIG. 1. Release of Ab from sedimentable deposits by chelators.
Frontal cortex from an AD brain was homogenized in PBS, pH 7.4, with
or without increasing concentrations of TPEN (A), EGTA (B), or BC (C).
Following centrifugation, Ab in the supernatants was visualized by
Western blot using anti-Ab monoclonal antibody WO2 (lower panels),
and quantified by densitometry (graphs above corresponding blots).
Although there is considerable variation in the optimum chelator con-
centration for the maximal recovery of Ab from case to case, these data
are representative of 17 AD cases.
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Ab soluble extraction occurred at about 0.1 mM for EGTA and
2 mM for TPEN (although there was considerable case-to-case
variation, and the case illustrated in Fig. 1A had an extraction
peak in response to 0.1 mM TPEN). Both TPEN and EGTA were
less effective at extracting Ab when present at concentrations
in the millimolar range, and EGTA at $2 mM abolished the
signal for Ab (Fig. 1B). In contrast, BC elicited a concentration-
dependent increase in Ab extracted from AD tissue (Fig. 1C)
plateauing at 10 mM. This finding is of interest because BC is
highly selective for Cu(I), and the result is compatible with our
recent finding that Ab rapidly binds and reduces Cu(II) to Cu(I)
(6, 23), suggesting that a proportion of Ab assembly is mediated
by Cu(I).
Insulin-degrading enzyme, a zinc-metalloproteinase, has
been reported to cleave Ab in the brain and in biological fluids
(15). To determine whether chelator-mediated augmentation of
Ab solubilization was due to inhibition of this enzyme, we also
performed homogenizations in the presence of 1 mM N-ethyl-
maleimide, a potent inhibitor of insulin-degrading enzyme.
Enhancement of Ab signal was not observed above that of PBS
alone (data not shown). To determine whether other enzymatic
activities may be artifactually modifying the data, we com-
pared extraction of the brain Ab at 4 °C to extraction at 37 °C.
There was no decrease in Ab signal to suggest enhanced deg-
radation at the higher temperature. These controls suggest
that inhibition of Ab-cleaving enzymatic activities by chelators
does not contribute to the generation of soluble Ab under these
conditions.
To characterize the metal ions participating in the precipi-
tation of brain-derived Ab and to investigate the nonlinear
response of Ab extraction in the presence of EGTA or TPEN, we
added additional metal ions to the extraction system. The pres-
ence of Cu(II) or Zn(II) in the PBS homogenization buffer
abolished the increased extraction of Ab caused by chelator
treatments (data not shown). Also, the presence of additional
Zn(II) ($5 mM) or Cu(II) ($50 mM) in the homogenization buffer
without chelator abolished extraction of Ab due to treatment
with PBS alone (Fig. 2A). Therefore, these metal ions can
modulate the solubility of Ab in this system.
The presence of Cu(II) at 5 mM in the PBS homogenization
buffer without chelator increased the extraction of Ab by PBS
(Fig. 2A). At pH 7.4, Zn(II) induces far more Ab aggregation
than Cu(II), hence this result may be due to Cu(II) displacing
Zn(II) from Ab. At 20 mM, Cu(II) induces the appearance of an
apparent SDS-resistant Ab dimer, which may be due to an
oxidative modification of the peptide or may represent an in-
termediate produced during the process of Ab aggregation.
Because millimolar concentrations of TPEN or EGTA unex-
FIG. 2. The effect of metals upon the solubility of brain-de-
rived Ab. A, Zn(II) and Cu(II) inhibit the solubilization of Ab by PBS
extraction. Specimens of AD frontal cortex were homogenized in the
presence of PBS or varying concentrations of Cu(II) (as sulfate) or Zn(II)
(as sulfate). After centrifugation, Ab in the supernatants was visualized
as described in Fig. 1. B, Ab in metal-depleted deposits is liberated into
the soluble phase by Mg(II) and Ca(II). Samples of AD frontal cortex
were homogenized in 2 mM EGTA, a condition that consistently abol-
ishes the release of Ab (see Figs. 1 and 3) and removes Zn(II), Cu(II),
and other metal ions from the solid phase of the homogenate. After
centrifugation, the remaining (metal-depleted) pellets were treated
with PBS (pH 7.4) alone, 2 mM Mg(II) in PBS, or 2 mM Ca(II) in PBS and
then centrifuged again. Data shown are representative of Ab in the
soluble fraction of the three treated samples, visualized as in Fig. 1.
FIG. 3. Patterns of chelator-mediated release of brain Ab in AD
and age-matched, non-AD tissue. Post-mortem samples of AD fron-
tal cortex (n 5 9) and age-matched controls (n 5 8) were treated with
PBS, TPEN, EGTA, or BC (chelators at 0.1 and 2 mM), and soluble Ab
was assayed by Western blot. A, the soluble material from the seven
treatment conditions of each individual case were initially compared on
the same blot. An iterative process was used to arrive at the final Ab
concentration for each sample (per g, wet weight) that involved multiple
blots quantified by densitometry with reference to two standards of
synthetic Ab1–40 (1 and 5 ng) as well as an 8 M urea extract of the
starting tissue. The upper panel of A shows a representative blot of
soluble Ab extracted from an AD case. The lower panel of A shows a
representative blot of soluble Ab extracted from a control (AC). For the
purposes of the illustration, similar densities of Ab signal in both the
AC and the AD cases shown were achieved by loading more sample onto
the AC blot and by slightly prolonging its exposure. However, when
normalized against synthetic peptide standards, the amount of Ab/g of
brain sample in typical AC specimens was less than AD (see Table II).
B, a graphical representation of the effects of chelator-mediated release
of brain Ab derived from data in Table II, which summarizes averaged
(6S.E.) data from the AD and AC groups, where the amount of soluble
Ab extracted by the six chelator treatments is expressed as a proportion
of the amount of Ab solubilized by treatment with PBS alone (normal-
ized to 100%) for each individual case.
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pectedly suppressed Ab resolubilization, we suspected that
Mg(II) or Ca(II) may participate in the resolubilization of Ab.
Mg(II) and Ca(II) are more abundant than Cu(II) and Zn(II) in
brain samples. Therefore, given the relative affinities of the
chelators used, sequestration of Mg(II) and Ca(II) would re-
quire higher chelator concentrations than those necessary to
complex Zn(II) and Cu(II). Samples of frontal cortex (0.5 g)
from AD were homogenized in 2 mM EGTA, a condition that
consistently abolishes the solubilization of Ab (see Fig. 3) while
removing Zn(II), Cu(II), and other metal ions from the solid
phase of the homogenate. The homogenates were centrifuged at
100,000 3 g for 30 min, and the supernatants were discarded.
The remaining (metal-depleted) pellets were rehomogenized in
a further 2 ml of PBS (pH 7.4) alone, 2 mM MgCl2 in PBS, or 2
mM CaCl2 in PBS, and the homogenates were subjected to
centrifugation again at 100,000 3 g. Ab in the soluble fraction
was visualized by Western blot with W02 as described. When
Mg(II) (2 mM) or Ca(II) (2 mM) was added to the homogenization
buffer, there was no appreciable alteration in the extraction of
soluble Ab (data not shown). However, when supplemented to
the pellet fraction of a brain homogenate previously depleted of
metals by treatment with 2 mM EGTA during homogenization,
Mg(II), and to a lesser extent Ca(II), both resolubilized the
sedimentable Ab (Fig. 2B). Taken together, these data indicate
that although removal of metal ions like Zn(II) and Cu(II) may
be necessary for the resolubilization of Ab deposits, the pres-
ence of Mg(II) and Ca(II) is required for the sedimentable Ab to
resolubilize. Therefore, the optimal chelator concentration for
the resolubilization of Ab deposits depends upon an interplay of
antagonistic factors, which may explain the nonlinear response
of Ab extraction to increasing chelator concentrations (Fig. 1, A
and B) and the case-to-case variability of the chelator concen-
trations required to achieve maximal extraction of Ab.
In order to investigate which metal ions are removed by
chelator treatments, we measured the amounts of various met-
als (aluminum, iron, magnesium, calcium, copper, and zinc)
remaining in the brain pellet after treatment with PBS with or
without chelator. Analysis of the effects of 0.1 mM TPEN was
performed first, since this treatment induced an increase in
soluble Ab in the first six AD samples analyzed and because
complete complexation of Mg(II) and Ca(II) was unlikely at
that concentration of chelator.
The observed increase in extractable Ab correlated with sig-
nificant depletion (30%) in zinc and, to a lesser extent, copper,
in each of 10 AD cases examined, when compared with PBS-
treated tissue. No other metal measured was significantly in-
fluenced by treatment at this concentration (Table I). A survey
of the metal content of pellets taken from AD brain homoge-
nates (n 5 2) treated with the complete range of chelator
concentrations described in Fig. 1, confirmed that EGTA treat-
ment at $2 mM depleted (.30%) the sample of zinc, calcium,
and magnesium, whereas treatment with TPEN at similar
concentrations depleted zinc, copper, calcium, and iron. Meas-
urement of metals remaining in the pellet following treatment
of these samples over the range of BC concentrations studied
indicated that none of the metals was depleted (data not
shown). Since BC has an affinity for Cu(I) that is 13 orders of
magnitude greater than for Cu(II), the lack of detectable total
copper depletion caused by treatment with BC is not unex-
pected, since copper levels were relatively low in these prepa-
rations and the proportion of copper that exists as Cu(I) is
likely to be small.
To determine the consistency of chelator effects upon Ab
extraction from brain, we surveyed a larger sample of speci-
TABLE I
Residual metal levels following treatment of brain homogenates with TPEN
Frontal cortex from AD (n 5 10) was homogenized in the presence or absence of 0.1 mM TPEN and metal levels in postcentrifugation pellets were
determined using inductively coupled plasma atomic emission spectroscopy, normalized for the starting wet weight of the tissue sample. An
asterisk indicates significant difference from treatment with PBS alone on t test (p , 0.01). Results are shown 6S.E.
Zinc Copper Iron Calcium Magnesium Aluminum
PBS 50.7 6 4.9 11.9 6 1.5 227 6 28.8 202 6 28.3 197 6 39.1 44.0 6 46.2
TPEN 33.2 6 4.1* 9.8 6 1.7 239 6 31.7 210 6 37.0 230 6 39.2 65.0 6 45.0
TABLE II
Concentrations of Ab extracted by PBS, chelator, and 8 M urea treatment of AD and AC specimens
See legend of Fig. 3. Concentrations of Ab (in mg/g, normalized for specimen wet weight) extracted from AD and AC specimens by 8 M urea
(representing estimated “total” Ab content), PBS, and two chelators (0.1 and 2.0 mM) were compared. To illustrate the variation, data from each
case are shown. Percentage of the total is shown in parentheses.
AD subject
X 6 S.E.
1 2 3 4 5 6 7 8 9
Total Ab 22 77 12 80 15 24 8 33 10 31 6 9.3
PBS 0.2 (0.9) 1.3 (1.7) 0.1 (0.8) 0.3 (0.4) 0.9 (6.0) 0.5 (2.1) 0.4 (5.0) 1.6 (4.8) 0.6 (6.0) 0.7 6 0.2 (3.1 6 0.8)
TPEN, 0.1 mM 0.6 (2.7) 2.8 (1.7) 0.4 (3.4) 0.3 (0.4) 0.8 (5.3) 0.9 (3.8) 0.8 (10) 1.6 (4.8) 0.7 (7.0) 1.0 6 0.3 (4.3 6 0.9)
TPEN, 2 mM 0.3 (1.4) 1.8 (2.3) 0.9 (7.5) 0.8 (1.0) 2.0 (13) 1.3 (5.4) 1.2 (15) 2.9 (8.8) 0.5 (5.0) 1.3 6 0.3 (6.6 6 1.7)
EGTA, 0.1 mM 0.3 (1.4) 1.5 (1.9) 0.04 (0.3) 0.5 (0.6) 1.1 (7.3) 0.5 (2.1) 0.7 (8.8) 1.7 (5.2) 0.4 (4.0) 0.8 6 0.2 (3.5 6 1.0)
EGTA, 2 mM 0.1 (0.5) 0.8 (1.0) 0 (0) 0 (0) 0.2 (1.3) 0 (0) 0.1 (1.3) 0.5 (1.5) 0.1 (1.0) 0.2 6 0.1 (0.7 6 0.2)
BC, 0.1 mM 0.14 (0.6) 1.8 (2.3) 0.9 (7.5) 1.4 (1.8) 1.2 (8.0) 0.9 (3.8) 1.6 (20) 3.1 (9.4) 0.5 (5.0) 1.3 6 0.4 (6.5 6 1.9)
BC, 2 mM 0.8 (3.6) 3.3 (4.3) 0.8 (6.7) 1.6 (2.0) 1.7 (11.3) 1.5 (6.3) 2.3 (28.8) 3.7 (11.2) 1.5 (15.0) 1.9 6 0.3 (9.6 6 2.7)
AC subject
X 6 S.E.
1 2 3 4 5 6 7 8
Total Ab 0.7 0.5 1.0 4.2 2.7 3.2 3.6 0.5 2.1 6 0.52
PBS 0.17 (24) 0.16 (32) 0.03 (3.0) 0.13 (3.0) 0.18 (6.7) 0.11 (3.4) 0.66 (18.3) 0.06 (12) 0.19 6 0.07 (12.8 6 3.9)
TPEN, 0.1 mM 0.12 (17) 0.17 (34) 0.10 (10) 0.29 (6.9) 0.10 (3.7) 0.10 (3.1) 0.60 (16.7) 0.08 (16) 0.19 6 0.07 (13.4 6 3.7)
TPEN, 2 mM 0.22 (31) 0.17 (37) 0.10 (10) 0.38 (9.0) 0.26 (9.6) 0.09 (2.8) 1.1 (30) 0.09 (18) 0.30 6 0.12 (18.4 6 4.5)
EGTA, 0.1 mM 0.39 (55.7) 0.22 (44) 0.17 (17) 0.28 (6.7) 0.15 (5.5) 0.12 (3.8) 1.0 (27.8) 0.10 (20) 0.30 6 0.1 (22.6 6 7.0)
EGTA, 2 mM 0.15 (21.4) 0.03 (6.0) 0.03 (3.0) 0 (0) 0 (0) 0.04 (1.25) 0.2 (5.5) 0 (0) 0.06 6 0.03 (4.6 6 2.7)
BC, 0.1 mM 0.09 (12.9) 0.15 (30) 0.15 (15) 0.20 (4.8) 0.18 (6.7) 0.08 (2.5) 0.98 (27.2) 0.08 (16) 0.23 6 0.11 (14.3 6 3.7)
BC, 2 mM 0.03 (4.3) 0.04 (8.0) 0.15 (15) 0.24 (5.7) 0.30 (11) 0.08 (2.5) 1.16 (32) 0.10 (20) 0.26 6 0.14 (12.3 6 3.5)
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mens using two chelator concentrations (0.1 and 2 mM), and
also measured the total amount of Ab in the samples by 8 M
urea solubilization. After measuring the effects of treatment
with the three chelators upon AD (n 5 9) and AC (n 5 8) brain
samples, a significant pattern emerged (Fig. 3). For AD cases,
significant increases of solubilized Ab, compared with the base-
line amount liberated by PBS treatment, were induced by
TPEN at 2 mM (2.7-fold, p , 0.001) and BC at 0.1 mM (2.8-fold,
p , 0.005) and at 2 mM (4.1-fold, p , 0.001). The effects of
chelators upon the release of Ab from the AC group were
markedly attenuated and therefore did not reach significance
with the exception of the effect of 0.1 mM EGTA, which induced
a significant increase (2-fold, p , 0.01). These data support the
possibility that Zn(II) and Cu(I) maintain the aggregated state
of Ab in AD brain but are less important in the architecture of
Ab aggregates in AC. EGTA (2 mM) inhibited the extraction of
Ab in both AD (decreased 80%, p , 0.001) and AC (decreased
50%, not significant) groups. This result is compatible with the
extraction of Ca(II) and Mg(II) from the tissue homogenates,
since these are metal ions that are required for the release of
Ab from deposits that have been depleted of zinc and copper
(Fig. 2). The cases analyzed in Fig. 3 were also assayed with
reference to the total amount of Ab extracted from the individ-
ual brain specimens (Table II). The concentration of total Ab in
the AD specimens was much greater (31 mg/g) than the total
amount in the AC samples (2.1 mg/g). The concentration of Ab
in AD brains that was extracted by PBS alone was 0.7 6 mg/g,
representing 3.1% of total Ab. The amount of Ab in AD brain
extracted by a single treatment with 2 mM BC increased sig-
nificantly to 1.9 6 mg/g, representing 9.6% (range 2.0–28.8%) of
total Ab. This proportion is likely to be an underestimate of the
amount of Ab that is assembled by biometals, since the result
was achieved by exposing the individual brain specimens to
only one brief chelator treatment. Repeated extraction cycles
resulted in further Ab release, up to 50% of the starting values.
We limited the highest concentration of BC to 2 mM for com-
parison with other chelators at equimolar concentrations, be-
cause our initial data (Fig. 1) indicated that millimolar concen-
trations of TPEN and EGTA suppressed Ab solubilization.
Treatment of AD specimens with chelators generated an
apparent SDS-resistant Ab dimer (immunoreactivity migrat-
ing at approximately 8.6 kDa) that was not evident when the
specimen was treated with PBS alone in over 60% of cases (Fig.
4A). Frequently, the appearance of an 8.6-kDa Ab species was
not accompanied by a proportional increase in the amount of
apparent Ab monomer (Fig. 4A). These findings are relevant
because SDS-resistant dimeric forms of Ab purified from AD
brain have been reported to possess increased neurotoxic prop-
erties (16). The possibility that there is a specific metal ion-
mediated abnormality of neurotoxic Ab dimer assembly is be-
ing investigated further.
We analyzed Western blots of brain extracts with antibodies
that are specific for AbX-40 (G210) and AbX-42 (G211) (Fig.
4B), since the latter Ab subspecies is enriched in AD amyloid
plaques (17). We found that treatment with BC significantly
increased the solubilization of both Ab subspecies in AD sam-
ples, indicating that AbX-42, while less soluble than the more
abundant AbX-40 (18) is nonetheless released by chelation of
Cu(I).
DISCUSSION
These data indicate that there is a pool of Ab within the
affected neocortex in AD that is held in sedimentable aggre-
gates by metal ions, likely to be Cu(I) and Zn(II), and that these
aggregates are solubilized by treatment with chelators. Mg(II)
and Ca(II) were found to be essential for the release of Ab. The
microanatomical site of these collections cannot be determined
by our methods, but it is likely to be extracellular, since this is
where Ab deposition in AD is readily demonstrable by morpho-
logical techniques and because chelator treatment of AC tissue
(possessing much less extracellular plaque deposit) did not
release as much Ab. The possibility of the artifactual combina-
tion of cellular metal ions with soluble Ab leading to Ab pre-
cipitation as a consequence of the tissue homogenization must
also be considered. However, since the precipitated fraction of
Ab in AD neocortex is much greater than the soluble cellular
pool, this possibility is unlikely to contribute substantially to
the phenomenon that we have observed. Other recent observa-
tions detecting enrichment of zinc, copper, and iron in amyloid
deposits by histological means (4) support the likelihood that
our observations reflect the chemical structure of Ab assembly
in amyloid deposits. Ab-associated, Zn/Cu-metalloproteins apo-
lipoprotein E (19) and a-2-macroglobulin (20–22), may also
participate in the reactions we have described.
Our data support the development of chelator compounds as
chemotherapeutic agents for AD. One previous clinical trial of
a chelator compound, desferrioxamine, was reported to signif-
icantly arrest the progression of the disease (14), but no further
attempts to reproduce this finding have been reported. Desfer-
rioxamine, like all chelators, is not perfectly specific for a
particular metal ion, and although the desferrioxamine trial
was thought to target Al(III), it is possible that the beneficial
effect of the treatment was due to chelation of Fe(III), Cu(II),
FIG. 4. Dissection of some components of metal ion-assembled
brain Ab deposits. A, extraction of soluble, SDS-resistant Ab dimers
by chelator treatment. Shown is a representative Western blot of the
AD samples that exhibit the release of a soluble Ab dimer when treated,
as in Fig. 3, with 0.1 and 2 mM TPEN, EGTA, or BC. B, treatment with
chelators promotes the solubilization of Ab40 and Ab42 from AD brain
tissue. A representative AD specimen was divided and treated with
PBS 6 5 mM BC, or 8 M urea to estimate total Ab content (T). Western
blots of the extracts were probed with monoclonal antibodies WO2
(raised against residues 5–16, recognizing many Ab subspecies includ-
ing Ab40 and Ab42), G210 (raised against residues 35–40, recognizing
Ab40), or G211 (raised against residues 35–42, recognizing Ab42).
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and Zn(II). Our current findings indicate that an ideal thera-
peutic to dissolve Ab amyloid would involve a compound that is
relatively selective for Cu(I), Zn(II), and possibly Fe(III); that
does not sequester Mg(II) or Ca(II); and that coordinates metal
ions in the cerebral amyloid mass but not systemically.
We have recently concluded a larger study comparing soluble
and insoluble Ab in AD and AC brains and have found a
significant correlation between the PBS-extractable Ab compo-
nent and disease severity.2 Although representing only a small
portion of the total Ab load, an approximate 3-fold difference in
the levels of the most readily mobilized Ab fraction distin-
guished AD from non-AD in an age-matched population. The
present study suggests that 4–7-fold increases in PBS-extract-
able Ab can be achieved by direct chelation. At the concentra-
tions used, this effect is observed without apparent impact
upon the solubility of other proteins. We have observed that
chelator concentrations as low as 4 mM were effective at resolu-
bilizing Ab deposits from AD brain samples, which indicates
that delivering an effective biometal-depleting compound to the
amyloid load in vivo may not necessitate biologically incompat-
ible doses. Clearly, compounds targeted to the dissolution of
aggregated amyloid only have promise as therapeutic agents if
the resolubilized and potentially toxic Ab can be effectively
cleared from the AD brain.
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